NERM
JAZZ icon

New England Research & Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

New England Research & Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,027
Closed -$533K – 162
2025
Q2 		$533K Sell
5,027
-23
-0.5% -$2.5K 0.25% 102
2025
Q1 		$627K Buy
+5,050
New +$659K 0.32% 94

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

New England Research & Management's JAZZ Position: Q3 2025 in Review

New England Research & Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2025, closing a stake of 5,027 shares — an estimated $533K sold.

New England Research & Management first reported a position in JAZZ in Q1 2025 and held it in 2 quarters. The position peaked at $627K in Q1 2025. 503 funds tracked by Wall St. Rank hold JAZZ as of Q3 2025.

  • New England Research & Management reported no remaining Jazz Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • New England Research & Management sold 5,027 Jazz Pharmaceuticals shares in Q3 2025, an estimated $533K.
  • New England Research & Management first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • New England Research & Management's Jazz Pharmaceuticals position peaked at $627K in Q1 2025.
  • 503 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2025.

Based on New England Research & Management's 13F filing for Q3 2025, filed 6 Oct 2025.